US/UK/Canada

Share

Quotes

Our expanding portfolio of innovative, image-guided laser ablation solutions is designed to meet the new and challenging medical treatment requirements in the growing field of minimally invasive, interventional MR procedures.
Lars-Erik Eriksson, CEO of CLS
The Access-i software and the agreement with Siemens Healthineers is yet another step towards CLS’s goal to build the next generation of integrated, workflow-optimized solutions for precision ablation.
Dan Mogren, CCO at CLS
The Access-i software and the agreement with Siemens Healthineers is yet another step towards CLS’s goal to build the next generation of integrated, workflow-optimized solutions for precision ablation.
Dan Mogren, CCO at CLS
We are pleased and excited to continue our association with DMI as it demonstrates our relevance and effectiveness, in this area, compared with other leading products in the field of urology.
Dan Mogren, CCO
UTMB continues to choose our products for treatment of patients with early stage prostate cancer, or other tumor disease, in the prostate. UTMB has become an important reference for us in the USA-market and the collaboration with the hospital continues to develop in a positive way.
Dan Mogren, CCO
I am very pleased that Toronto General Hospital has chosen our products for its clinical study. We will in a systematic way get access to important data on how our products perform when used in MRI guided focal laser ablation treatment.
Lars-Erik Eriksson, CEO
It is very gratifying that UTMB choses to purchase our system and continue to use our products. Dr. Eric Walser has so far treated about 20 patients, with early stage prostate cancer, using CLS’ accessories for MR-guided focal laser ablation and the products are performing very well.
Dan Mogren, CCO
CLS’ goal for 2017, to initiate sales in the US market, has now been accomplished. We receive repeat orders from demanding customers. This indicates good marks for our products. In the long term I see huge opportunities for us to build a successful business in the US.
Dan Mogren, CCO
As previously announced two patients have received treatment. An image guided laser treatment procedure was carried out, aiming at reducing pain and decreasing /eliminating the vascular malformation, with an immediate positive outcome.
Dan Mogren, CCO at CLS
The relationship with UTMB and Dr. Eric Walser is important to us also in other ongoing discussions in the US. We believe that we are seeing the beginning of a commercial acceptance for our products’ features and pricing, and that we thereby are able to compete with bigger and more established suppliers within our market segment.
Dan Mogren, CCO at CLS
This is the first time we are part of this conference, targeting one of our main user groups, interventional oncologists. WCIO 2017 is an excellent forum for us to showcase our products and further expand our presence in the US market.
Dan Mogren, CCO at CLS
Pick a time period -
Tags ( Active)

The exercise period for CLS warrants of series TO 7 begins today

In June 2024, Clinical Laserthermia Systems AB (publ) (“CLS” or the “Company”) carried out a rights issue of shares and warrants of series TO 7 B (the “Rights Issue”). The exercise period for the warrants begins today, November 11, 2024 and runs up to and including November 22, 2024. One (1) warrant entitle the holder to subscribe for one (1) new B-share in CLS. The subscription price per B-share that is subscribed for through exercising the warrants has, in accordance with the terms and conditions for the warrants, been set to SEK 3.68. If all warrants are exercised, CLS will receive

CLS takes next step towards CE marking in neurosurgery by obtaining ISO certificate according to MDR and completion of study at Skåne University Hospital

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS or the "Company") today announces that the company has received ISO certificate in accordance with the new Medical Device Regulation (MDR) and that the follow-up of patients in the CLS-sponsored clinical study at Skåne University Hospital has now been completed. The company has thus achieved two very important milestones on the way to a market approval of the ClearPoint Prism® Neuro Laser Therapy System in Europe.CLS has obtained ISO certificate in accordance with MDR The change in the new Medical Device Regulation (MDR) places

New board member of CLS buys shares in the company and the CEO and EVP Operations increase their shareholdings

Lund, Sweden – Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that the Company's new Board member Peter Mantas, the CEO, Dan J. Mogren, and EVP Operations, Jimmy Johansson, have purchased a total of 22,000 Class B shares in CLS.Peter Mantas acquired 10,000 shares bringing his total holding to 10,000 Class B shares on Wednesday, November 6th. Dan J. Mogren completed the purchase of 8,000 shares on November 5th. After the transactions, Dan J. Mogren's total holding amounts to 30,939 Class B shares plus 632 Class B shares via Medinovus AB. Jimmy

CLS publishes interim report January – September 2024

Summary of the interim report (relates to the Group) First nine months (01/01/2024–09/30/2024) · Net sales totaled SEK 14,171,000 (SEK 3,817,000). · Profit/loss after financial items totaled SEK -39,130,000 (SEK -55,257,000). · Basic and diluted earnings per share totaled SEK -4,1 (SEK -24,7). · The equity ratio at September 30, 2024, was 85% (86%). The third quarter (07/01/2024 – 09/30/2024) · Net sales totaled SEK 5,409,000 (SEK 1,978,000). · Profit/loss after financial items totaled SEK -12,967,000 (SEK -17,247,000). · Basic and diluted earnings per share

CLS enters subscription undertakings and guarantee commitments for the redemption of warrants of series TO 7 B

Clinical Laserthermia Systems AB ("CLS" or the "Company") announces that the Company has entered into agreements of subscription undertakings and guarantee commitments (so-called "top-down guarantee") for the upcoming redemption of warrants of series TO 7 B ("TO 7 B”). The redemption period begins on November 11, 2024. The subscription undertakings and the guarantee commitment have mainly been entered into by the Company's largest shareholder, among them Khattar Holdings, and comprise a total of approximately 14.5% of the number of outstanding warrants and guarantee commitments of

CLS focus entirely on its successful neurosurgery business positioning the company for sustainable high-margin growth with a more streamlined operation

Lund, Sweden – Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces it will focus entirely on its successful neurosurgery business to drive sustainable high-margin growth with a streamlined operation, positioning the company for long-term success. Refining the Company's direction is being done in consideration of current market conditions and opportunities and follows on the strategic review conducted in May this year.­  With the recent addition of Peter Mantas and Peter Max to the board, the latter as the new Chairman, the Company is committed to prioritizing

Bulletin from the Extraordinary General Meeting on 21st of October in Clinical Laserthermia Systems AB

Today, October 21, 2024, an Extraordinary General Meeting was held in Clinical Laserthermia Systems AB, org. no. 556705–8903. Below is a summary of the decisions taken.Election of the Board of Directors (Item 6) The general meeting resolved to re-elect Lars-Erik Eriksson, Marika Crohns, and Sandra Brandmeier as board members. Furthermore, the general meeting elected Peter Mantas and Peter Max as board members.   The newly appointed board elected Peter Max to be the chairman of the board immediately after the general meeting.     For more information about CLS, please

CLS reschedules the publication of the Q3 2024 interim report to an earlier date and invites to a webcast

Lund, Sweden – Clinical Laserthermia Systems AB (publ) ("CLS" or “the Company") today announces that the Company is bringing forward the publication of its interim report for the third quarter 2024. The new date for publication is Thursday 31 October 2024. The previously announced date was Friday, November 15, 2024.The reason for bringing forward the interim report to an earlier date is linked to the redemption of warrants of series TO 7 B that will take place during the month of November. In connection with the publication of the report, CLS invites investors, analysts and media to a

Notice of Extraordinary General Meeting at Clinical Laserthermia Systems

The shareholders of Clinical Laserthermia Systems AB, 556705-8903, are hereby invited to an Extraordinary General Meeting on Monday, October 21, 2024, at 10:00 AM at Scheelevägen 4, Medicon Village, Lund.Right to participate and registration Shareholders wishing to participate in the meeting must: · Be registered in the shareholders' register maintained by Euroclear Sweden AB by Friday, October 11, 2024, and · Notify the company no later than Tuesday, October 15, 2024, in writing to Clinical Laserthermia Systems AB, Medicon Village, Scheelegatan 2, 223 63 Lund. Notification can

CLS announces proposal for changes to the Board of Directors

Lund, Sweden – Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announced that the Chairman of the Board of Directors Hans von Celsing and, Board member, Paolo Raffaelli, will resign from the Board of Directors at their own request. Peter Max and Peter Mantas are proposed as new members of the Board, the former of whom is also proposed as the new chairman of CLS. Furthermore, it is proposed that Lars Erik Eriksson, Sandy Brandmeier and Marika Crohns  remain  as members of the Board. The Nomination Committee supports this proposal. Notice of an Extraordinary General

Correction: Publication of CLS half-year report, 1 June – 30 June 2024

In the half-year report that was attached to the press release that was sent out today, August 23 at 8:51 a.m., two errors have been discovered, it has now been corrected by corrected pdf files being published on the company's website.The error was in the table of the consolidated cash flow on page 13; "Consolidated cash flow statement for the period". The incorrect version stated that:   1. The company's bridge loan of SEK 12.5 million was reported in the original report under "Cash paid to suppliers and employees" and not as "Proceeds from borrowings". 2. On the penultimate row

CLS publishes half-year report January – June 2024

Summary of the half-year report (relates to the Group) First semester (01/01/2024–06/30/2024)  · Net sales totaled SEK 8,762,000 (SEK 1,839,000). · Profit/loss after financial items totaled SEK -26,163,000 (SEK -37,980,000). · Basic and diluted earnings per share totaled SEK -0.02 (SEK -0.25). · The equity ratio on June 30, 2024, was 63% (-31%).  The second quarter (04/01/2024–06/30/2024)  · Net sales totaled SEK 5,622,000 (SEK 1,252,000). · Profit/loss after financial items totaled SEK -13,592,000 (SEK -16,516,000). · Basic and diluted earnings per share

CLS announces last day of trading with BTU and first day of trading in warrants of series TO 7

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.   Clinical Laserthermia Systems AB:s ("CLS" or the “Company") rights issue is now registered with the Swedish Companies

CLS announces outcome of rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE. The subscription period in Clinical Laserthermia Systems AB AB (publ) ("CLS"or the "Company") rights issue of B-shares and warrants (

Communique from the Annual General Meeting on Friday June 28th in Clinical Laserthermia Systems AB

Today, June 28th 2024, is the Annual General Meeting (the “AGM”) of Clinical Laserthermia Systems AB, 556705-8903. Below is a summary of the decisions taken. All decisions were taken with the required majority.Adoption of the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet (Item 8a) The AGM resolved to adopt the presented income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet.   Resolution regarding appropriation of the company's profit according to the adopted

CLS enters the Italian market for Focal Laser Ablation together with the Nationwide Italian Company Tecnogamma s.r.l.

Lund, Sweden - Clinical Laserthermia Systems AB (publ) (CLS) today announced it has entered into an exclusive distribution agreement with Tecnogamma s.r.l. Company (Tecnogamma) to market and sell the CLS TRANBERG[®] product portfolio for urology in Italy.The interest for focal therapies is growing in Italy and as previously reported the first cases using the CLS TRANBERG® Thermal Therapy System in prostate cancer patients were performed in April 2024 at University Hospital San Luigi Gonzaga in Turin by Prof. Francesco Porpiglia, Head of the Urological division. CLS is now entering into an

Recruitment of Glioblastoma Patients to the CLS-sponsored Clinical Study at Skåne University Hospital is now Completed

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS or the "Company") today announces that the recruitment of patients to the clinical study, sponsored by CLS and co-funded by ClearPoint Neuro Inc, at Skåne University Hospital in Sweden is now completed. In the study a total of 14 patients with glioblastoma have been treated with MR-guided laser ablation.The study is a single-center, non-randomized prospective study with the aim of evaluating the safety and feasibility of minimally invasive MRI-guided laser ablation (also named as Laser Interstitial Thermal Therapy or LITT) of tumor

Clinical Laserthermia Systems publishes supplementary prospectus regarding ongoing rights issue

Clinical Laserthermia Systems AB (publ) (“CLS” or the ”Company”) has drafted a supplementary prospectus (the ”Supplementary Prospectus”) to the EU growth prospectus approved and registered by the Swedish Financial Supervisory Authority (SW: Finansinspektionen) on June 10, 2024 (the “Prospectus”). The Supplementary Prospectus has today, June 20, 2024, been approved and registered by the Swedish Financial Supervisory Authority.The Prospectus has been drafted in connection with the ongoing rights issue of units consisting of new B-shares and warrants of series TO 7 B, which was resolved by the

CLS receives additional order for ClearPoint Prism products corresponding to approximately SEK 7.5 million

Lund, Sweden – Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that the Company has received additional orders from ClearPoint Neuro, Inc (Nasdaq:CLPT). The order, which has a value of approximately SEK 7.5 million, is for ClearPoint Prism products and is part of ClearPoint Neuro's full market launch in North America, which began in early June this year, and follows previous orders that CLS received around the turn of the year 2023/2024 totaling approximately SEK 10.5 million.­­ CLS's collaboration with ClearPoint Neuro Inc aims to develop and

CLS publishes prospectus in connection with forthcoming rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE. The Board of Directors of Clinical Laserthermia Systems AB AB (publ) ("CLS" or the “Company”) announced on 30 May 2024 its

Clinical Laserthermia Systems publishes annual report for 2023

Lund, Sverige – Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) today published its annual report for fiscal year 2023.­­ Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) today published its annual report for fiscal year 2023. The report is available on the company’s website https://clinicallaser.se/. It is also attached to this press release.   An English version of the annual report will be published on the company’s website in the beginning of July.   Contact information: Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)Tel:

BioStock: CLS’ partner initiates full market release in the US

CLS’ commercial partner ClearPoint Neuro has initiated its full market release of the ClearPoint Prism 3T Neuro Laser Therapy System, which is based on CLS’ technology. The launch took place June 1-4 at the 2024 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting in Nashville.Read the full article at biostock.se : https://www.biostock.se/en/2024/06/cls-partner-initiates-full-market-release-in-the-us/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

First Clinical Data from the Investigator-initiated study with CLS Focal Laser Ablation system at the University Hospital Magdeburg will be presented at the Nordkongress in Lübeck 13-15 June 2024

Lund, Sweden - CLS today announces that first clinical data from the PRO-FLA study (Fokale Laserablation (FLA) zur fokalen Behandlung des lokal begrenzten Prostata-karzinoms) using the CLS TRANBERG® Thermal Therapy system for focal laser ablation will be presented at the Nordkongress in Lübeck 13-15 June 2024. An abstract with the title “Ultrasound-guided Focal Laser Ablation in Localized Prostate Cancer within the Pro-FLA Study – Oncological outcome after 6 months” has been accepted for an oral presentation to be held 13 June.The presentation is part of the scientific program of the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe